| Revenue | NOK 0 | — |
| EBITDA | NOK -265K | -334% |
| Net profit | NOK -237K | -122% |
| Total assets | NOK 16,4M | -1% |
| Equity | NOK 16,1M | -1% |
| Employees | 0 | — |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −233 | −237 | −76 | −75 | −61 | −265 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −233 | −237 | −76 | −75 | −61 | −265 |
| Net financials | 0 | −740 | 1 281 | 6 899 | 1 143 | 28 |
| Profit before tax | −553 | −977 | 1 205 | 6 824 | 1 082 | −237 |
| Tax | −0 | −0 | 255 | −162 | −0 | −0 |
| Net profit | −553 | −977 | 951 | 6 986 | 1 082 | −237 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 13 052 | 15 086 | 16 313 | 23 286 | 16 655 | 16 447 |
| Equity | 13 032 | 15 055 | 16 005 | 22 992 | 16 357 | 16 120 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 20 | 31 | 145 | 295 | 298 | 328 |
| Total debt | 20 | 31 | 308 | 295 | 298 | 328 |
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Dr. Bernd Phister | Company | 30.1% | 30.1% | 2024 |
Alimentos Ventures Gmbh | Company | 21.8% | 21.8% | 2024 |
Farvatn Venture As | Company | 12.1% | 12.1% | 2024 |
| Individual | 6.0% | 6.0% | 2022 | |
Michael Gryseels | Company | 6.0% | 6.0% | 2024 |
Aspara Investments Pte Ltd | Company | 6.0% | 6.0% | 2024 |
Carl Alexander Hormos | Company | 6.0% | 6.0% | 2024 |
| Individual | 6.0% | 6.0% | 2022 | |
Kbioconsult Gmbh | Company | 6.0% | 6.0% | 2024 |
Peter Ernst Wild | Company | 5.9% | 5.9% | 2024 |
Norsk Bioakva As | Company | 3.0% | 3.0% | 2024 |
Elkstone Capital International | Company | 3.0% | 3.0% | 2024 |
| Person | Role here | Other companies |
|---|---|---|
| Carsten Alexander Krome | Chairman | 0 companies |